A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 495 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally... September 5, 2022 AI and remote monitoring are shaping a new patient journey in... August 26, 2025 Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death... March 6, 2020 ¿El azúcar provoca cáncer? September 20, 2022 Load more HOT NEWS New on NCI Websites for June 2018 What to Know About At-Home DNA Tests for Detecting Cancer Risk Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab... Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone...
